+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PTC Therapeutics - logo

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

From
From
From
Pontine Glioma (Oncology) - Drugs in Development, 2021 - Product Thumbnail Image

Pontine Glioma (Oncology) - Drugs in Development, 2021

  • Report
  • October 2021
  • 649 Pages
From
From
From
From
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • February 2021
  • 43 Pages
From
mRNA Therapeutics and Vaccines: Key Opinion Leaders - Product Thumbnail Image

mRNA Therapeutics and Vaccines: Key Opinion Leaders

  • Report
  • September 2021
  • 116 Pages
From
From
Loading Indicator